Following its mid-year report and its entrance into the U.S. OTCQX (ASX: EXL; OTCQX: ELLXF), Elixinol was recently featured in The Green Fund, Hemp Industry Daily, and Yahoo! News.
The Green Fund: Elixinol — the sleeping giant of the Hemp Market
In this article, The Green Fund breaks down the hemp industry’s exciting recent growth, with a spotlight on Elixinol’s new presence on the U.S. OTCQX (OTCQX: ELLXF).
The U.S. hemp market is on track to reach $1 billion by the end of 2018. And by 2022, hemp CBD extract alone is projected to reach or surpass $22 billion.
Factoring into the assessment was Elixinol Global’s half-yearly report which highlights Elixinol’s global expansion and financial successes. (Read full ASX report here.)
The article highlights Elixinol’s growth during the first half of 2018. It says, “According to the company’s 2018 mid-year results release, Elixinol is following a disciplined approach to driving growth, supported by investment in farming and production capabilities in Colorado.
“A channel sales strategy is in place to drive growth in the higher-margin e-commerce, national accounts, mid-market accounts and private label branded products segments.”
Hemp Industry Daily: Australian CBD maker raises $29 million, ups investment in Japan
Hemp Industry Daily covered Elixinol Global’s (EXL) increased investment in Elixinol Japan, on the heels of its growth in the U.S. and Europe. Elixinol Global CEO, Paul Benhaim stated his support for the growing hemp-derived product market in Japan, “…this market is poised for growth and that the regulatory support is there,” he said.
The announcement comes less than a week after EXL announced a capital raise and further increased its stake in the hemp foods market as well.
Yahoo! News: Elixinol Celebrates OTC Trading of Australian-Based Parent Company Elixinol Global
Yahoo! Finance recently featured Elixinol Global’s (EXL) entrance into the U.S. OTCQX under ticker symbol ELLXF.
The trading enables U.S. investors to more easily join Australian investors as EXL continues its global expansion.
“With EXL’s half-yearly report issued in August 2018, the company posted strong revenue growth and a maiden profit for the group, driven considerably by Colorado-based industrial hemp division, Elixinol.
Elixinol’s increased sales were lead (sic) by cannabidiol (CBD) private label sales with e-commerce, mid-market and bulk sales also showing a strong performance. EXL was the only ASX-listed company in this sector to post a profit.”